Saniona AB
Saniona was informed today that Novartis plans to acquire Cadent Therapeutics, in which Saniona holds an ownership stake of approximately 3%
Saniona was informed today that Novartis plans to acquire Cadent Therapeutics, in which Saniona holds an ownership stake of approximately 3%
PRESS RELEASE
December 17, 2020
Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced it was informed that Novartis plans to acquire Cadent Therapeutics, in which Saniona holds an ownership stake of approximately 3%. The financial impact of this potential acquisition to Saniona is not known at this time.
Novartis and Cadent each announced today that Novartis intends to acquire all of the outstanding capital stock of Cadent. Upon the closing of the transaction, Cadent will receive a $210 million upfront payment and will be eligible for up to $560 million in milestone payments, for a total potential consideration of $770 million. Saniona holds an ownership stake of approximately 3% in Cadent resulting from Cadent’s previous acquisition of the Saniona spin-out Ataxion, which was created to leverage Saniona’s ion channel expertise for the treatment of movement disorders.